FTSE 100 Market news covers the latest developments for the FTSE 100 Index, which tracks the 100 most highly capitalised blue‑chip companies listed on the London Stock Exchange.
This category includes updates on company admissions and delistings, quarterly and annual results, mergers and acquisitions, board appointments and departures, regulatory news and policy changes.
AstraZeneca plc (LON:AZN) today announced detailed results from the landmark Phase III DAPA-HF trial that showed Farxiga on top of standard of care reduced both the incidence of cardiovascular death..
Pursuant to Listing Rule 9.6.14(2) Micro Focus International (LON:MCRO) today announced that Kevin Loosemore, Executive Chairman, has been appointed to the Board of De La Rue plc as a non-executive..
AstraZeneca plc (LON: AZN) today announced that the Phase III TULIP 2 trial for anifrolumab, a potential new medicine for the treatment of systemic lupus erythematosus (SLE), met its primary..
Vodafone Group plc (LON: VOD) will be the Official Communication Partner of Porsche Motorsport when the automobile manufacturer enters the 2019/2020 ABB FIA Formula E Championship. Formula E is the..
AstraZeneca plc (LON:AZN) today announced positive results from the Phase III ETHOS trial for triple-combination therapy Breztri Aerosphere, formerly PT010, in patients with moderate to very severe chronic obstructive pulmonary..
Anglo American plc (LON:AAL) today announced the value of rough diamond sales (Global Sightholder Sales and Auction Sales) for De Beers’ seventh sales cycle of 2019, amounting to $280 million...
AstraZeneca plc (LON:AZN) today announced that the US Food and Drug Administration has granted Orphan Drug Designation to Fasenra (benralizumab) for the treatment of eosinophilic oesophagitis (EoE). EoE is a..
Bunzl plc (LON:BNZL), the specialist international distribution and services Group, today publishes its half yearly financial report for the six months ended 30 June 2019. Financial results As reported under..
GlaxoSmithKline plc (LON/NYSE: GSK) today announced positive headline results from the pivotal DREAMM-2 open-label, randomised study of two doses of belantamab mafodotin (GSK2857916). The 196 patients in the trial had..
As part of its 2019 Interim Results on 22 August 2019, CRH PLC (LON:CRH) announced its intention to continue its share buyback programme with a further tranche of up to..
AstraZeneca plc (LON:AZN) today announced that it has agreed to buy a US Food and Drug Administration Priority Review Voucher for a total cash consideration of $95m from a subsidiary..
NMC Health PLC (LON:NMC), the leading Gulf Cooperation Council and international private healthcare operator, has today announced its results for the six months ended 30 June 2019. Key Highlights · Strong..
GlaxoSmithKline PLC (LON: GSK) ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, today announced positive headline results from its..
NMC Health PLC (LON:NMC) today announced that it intends to immediately initiate the process to seek shareholder approval for a share buyback programme. The buyback authority will require formal approval..
Antofagasta PLC (LON: ANTO) have today announced its half year report for the six months ended 30th June 2019. Antofagasta plc CEO Iván Arriagada said: “We have delivered robust financial..
AstraZeneca (LON: AZN) today announced that its partner FibroGen (China) Medical Technology Development Co., Ltd. (FibroGen China) has received marketing authorisation for roxadustat in China for the treatment of anaemia..
AstraZeneca plc (LON: AZN) today announced final overall survival results from the Phase III NEPTUNE trial, a randomised, open-label, multi-centre, global trial of Imfinzi (durvalumab) in combination with tremelimumab, an..
BHP Group (LON: BHP) have today announced that its ‘Results Presentation Year Ended 30 June 2019’ has today been submitted to the National Storage Mechanism and will shortly be available..
Persimmon Plc (LON:PSN) today announced its half year results for the six months ended 30 June 2019. Highlights “Improving the quality and service delivered to our customers remains our top..
Farxiga met primary endpoint in landmark Phase III DAPA-HF trial for the treatment of patients with heart failure DAPA-HF is the first heart failure outcomes trial with an SGLT2 inhibitor..
